Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol. 2018 Dec;15 (12):750-776
Ramzan M, Bakhsh S, Salam A. et al.Risk factors in urinary tract infection. Med Sci. 2004;2:50–5
Guidelines on Urological infections – European Association of Urology, 2020
Geerlings SE. Clinical Presentations and Epidemiology of Urinary Tract Infections. Microbiol Spectr (2016) Oct; 4(5)
Product Information Page
Costache RD et al. Xyloglucan + Gelose Combination versus Placebo as Adjuvant Therapy to First-Line Antimicrobials for Uncomplicated Urinary Tract Infection in Adults – Urologia Internationalis 2019;102:468–475.
Garcia-Larossa A, Alexe O.Efficacy and safety of a medical device versus placebo in the early treatment of patients with symptoms of a urinary tract infection: a randomised controlled trial . Clin. Microbiol. 5,1 (2016).
Flores –Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary Tract Infections: epidemiology, mechanisms of action and treatment options. Nat Rev Microbiol. 2015 May;13(5):269-84.
Guglietta A. Recurrent Urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis. Future Microbiol . 2017 Feb; 12 (3).
Utipro Plus AF Product Information Leaflet Rev.02.01.09.2019
T Cai et al. Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study – Future Microbiology, 2019; 14:1013-1021.
Healthcare Professionals Page
García-Larrosa and Alexe – Efficacy and Safety of a Medical Device versus Placebo in the Early Treatment of Patients with Symptoms of Urinary Tract Infection: A Randomized Controlled Trial, Clin Microbiol 2016, 5:1.
Salvatorelli N. et al. A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. Urol Int 2016;97:347–351.